DGAP-News: Vivoryon Therapeutics N.V.
/ Key word(s): Conference
09.09.2021 / 16:41
The issuer is solely responsible for the content of this announcement.
Vivoryon Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Halle (Saale) / Munich, Germany, September 9, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, announced today that Ulrich Dauer, PhD, the Company’s Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday September 13, 2021, at 7:00 am ET.
A replay of the webcast can be accessed from the Presentations & Webcasts page under News and Events on Vivoryon’s website, www.vivoryon.com. The replay will be archived on Vivoryon’s website for 30 days after the call.
For more information, please contact:
About Vivoryon Therapeutics N.V.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Vivoryon Therapeutics N.V.|
|Phone:||+49 (0)345 555 9900|
|Fax:||+49 (0)345 555 9901|
|Listed:||Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam|
|EQS News ID:||1232472|
|End of News||DGAP News Service|